Factors influencing Multiplate whole blood Impedance Platelet Aggregometry measurements, during aspirin treatment in acute ischemic stroke: A pilot study

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 8, 2013, Pages 830-838

  Jastrzȩbska, Maria ^a   Chełstowski, Kornel ^a   Wódecka, Aneta ^b   Siennicka, Aldona ^a   Clark, Jeremy ^a   Nowacki, Przemysław ^b  

^a Department of Laboratory Diagnostics and Molecular Medicine ^*  (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

aspirin resistance; impedance platelet aggregometry; proinflammatory factors; stroke; thromboxane TXB2; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; THROMBOXANE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD EXAMINATION; BRAIN ISCHEMIA; DRUG EFFICACY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; IMPEDANCE PLATELET AGGREGOMETRY; LEUKOCYTE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; ELECTRIC IMPEDANCE; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; STROKE; THROMBOXANE B2; TICLOPIDINE; VON WILLEBRAND FACTOR;

EID: 84888133611     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283655640     Document Type: Article

References (44)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelets therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Lö sche W, Boettel J, Kabisch B, Winning J, Claus RA, Bauer M. Do aspirin and other antiplatelet drugs reduce the mortality in critically III patients? Thrombosis 2012; 2012:720254.
3. Fuchs I, Frossard M, Spiel A, Riedmüller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts reccurrent ACS. J Thromb Haemost 2006; 4:2544-2552.
4. Sobol AB, Mochecka A, Selmaj K, Loba J. Is the a relationship between aspirin responsiveness and clinical aspects of ischemic stroke? Adv Clin Exp Med 2009; 18:473-479.
5. Tran HA, Anand SS, Hankey GJ, Eikelboom JW. Aspirin resistance. Thromb Res 2007; 120:337-346.
6. Cavalcanti de Oliveira D, Silva RF, Silva DJ, Correla de Lima V. Aspirin resistane: fact or fiction? Arg Bras Cardiuol 2010; 95:e91-e94.
7. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome-fact and fiction. Thromb Haemost 2011; 106: 191-202.
8. Akay OM, Canturk Z, Akin E, Bal C,Gulbas Z. Aspirin-resistance frequency: a prospective study in 280 healthy Turkish volunteers. Clin Appl Thromb Hemost 2009; 15:98-102.
9. Shenkman B, Matetsky S, Feper P, Hod H, Einav Y, Lubetsky A, et al. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. Thromb Res 2008; 122:336-345.
10. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009; 19:440-449.
11. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients. Diabetes 2007; 56:3014-3019.
12. Markuszewski L, Rosiak M, Golań ski J, Rysz J, Spychalska M, Wata?a C. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possibile factors predisposing to suboptimal platelet response to aspirin? BCPT 2006; 98:503-509.
13. Ashwin KA, Bairy KL, Vidyasagar S, Verma M, Prashanth CK, Sachidananda A. Aspirin resistance. Indian J Physiol Pharmacol 2007; 51:109-117.
14. Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention. J Am Coll Cardiol 2008; 51:1829-1843.
15. Ludovic D, Bal C, Patrick H. The basis of platelets: platelet and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients. Drugs 2010; 70: 9-14.
16. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28:1702-1708.
17. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25:166-181.
18. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HP, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120:631-635.
19. Rao GH, Michiels JJ. Aspirin resistance: does it exist? Semin Thromb Hemost 2007; 33:210-214.
20. Ivandic BT, Giannitsis E, Schlick P, Staritz P, Katus HA, Hohlfeld T. Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 2007; 53:614-619.
21. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009; 131:834-842.
22. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiple whole blood impedance platelet aggregometry and turbidometric platelet aggregation in healthy individuals. Platelets 2007; 18:199-206.
23. Chakroun T, Addad F, Abderazek F, Ben-Farhat M, Hamdi S, Gamra H, et al. Screening for aspirin resistance in stable coronary artery patients by tree different tests. Thromb Res 2007; 121:413-418.
24. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Circulation 2008; 118:1705-1712.
25. Kuliczkowski W, Witkowski A, Poloń ski L, Wata?a C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009; 30:426-435.
26. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006; 32:537-545.
27. Inglott S, Burgess C, Liesner R. The evaluation of impedance aggregometry to measure response yo ristocetin in children in type I von Willebrand disease pre and post intranasal DDAVP [abstract]. Haemophilia 2006; 12 (Suppl 2):30; Abstract PO903.
28. Lison S, Dick A, Giebl A. The evaluation of whole blood platelet aggregation in von Willebrand disease [abstract]. Haemostasiology 2009; 1:PP3; 2-2.
29. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Turuya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35:175-178.
30. Crescente M, Di Castelnuovo A, Lacoviello L, Vermylen J, Cerletti Ch. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. Thromb Haemost 2008; 99:14-26.
31. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1 dependent and independent platelet function assays with adverse clinical outcomes in aspirin treated patients presenting for cardiac catheterization. Circulation 2009; 120:2586-2596.
32. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115:2490-2496.
33. Guthikondal S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, et al. Increased platelet sensitivity among individuals with aspirin resistance-platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100:83-89.
34. Ohmori T, Yatomi Y, Nonaka Y, Kabayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway (s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 4:1271-1278.
35. Halawani SH, Williams DJP, Adefurin A, Webster J, Greaves M, Ford I. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. Thromb Haemost 2011; 106:240-247.
36. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380.
37. Boncler M, Luzak B, Ró z?alski M, Golań ski J, Rychlik B, Wata?a C. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb Res 2007; 119:209-216.
38. Boncler M, Rywaniak J, Szymań ski J, Potempa LA, Rychlik B, Wata?a C. Modified C-reactive protein interacts with platelet glycoprotein Iba. Pharmacol Rep 2011; 63:464-475.
39. Woodward M, Lowe GDO, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36:2143-2147.
40. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326:82-83.
41. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005; 101:71-76.
42. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drug 2007; 67:997-1026.
43. Evangelista V, Totani L, Rotondo S, Rotondo S, Lorenzet R, Tognoni G, et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005; 93:8-16.
44. Fatch-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42:99-103.